Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report) and keeping the price target at $21.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD’s rating is based on the recent FDA clearance of Verve Therapeutics’ IND application for their PCSK9 gene editing program, VERVE-102. This clearance is a significant milestone as it demonstrates regulatory confidence in the safety profile of VERVE-102, which is designed to treat heterozygous familial hypercholesterolemia and premature coronary artery disease.
The clearance allows for the expansion of VERVE-102’s clinical trials into the US, paving the way for larger Phase 2 and 3 studies. Additionally, the company’s strategic collaboration with Eli Lilly, which includes potential cost-sharing and profit-sharing arrangements, further strengthens the commercial prospects of VERVE-102. These factors combined suggest a promising outlook for Verve Therapeutics, justifying the Buy rating.
According to TipRanks, Jubinville, PhD is an analyst with an average return of -6.7% and a 34.78% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Tarsus Pharmaceuticals, and Crinetics Pharmaceuticals.